Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma

Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma

Anti-PD-L1 antibody monotherapy shows limited efficacy in a significant proportion of the patients. A common explanation for the inefficacy is a lack of anti-tumor effector cells in the tumor microenvironment (TME). Recombinant human interleukin-15 (hIL15), a potent immune stimulant, has been invest...

Full description

Bibliographic Details
Main Authors: Fei-Ting Hsu, Yu-Chang Liu, Chang-Liang Tsai, Po-Fu Yueh, Chih-Hsien Chang, Keng-Li Lan
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
PD-L1
IL15
colon cancer
melanoma
tumor microenvironment
Online Access:https://www.mdpi.com/2072-6694/13/8/1789

Internet

https://www.mdpi.com/2072-6694/13/8/1789

Similar Items